Company Description
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women’s health, and neurologic health.
The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Amro Albanna |
Contact Details
Address: 2569 Wyandotte Street, Suite 101 Mountain View, California 94043 United States | |
| Phone | 650 870 1200 |
| Website | aditxt.com |
Stock Details
| Ticker Symbol | ADTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001726711 |
| CUSIP Number | 007025109 |
| ISIN Number | US0070256047 |
| Employer ID | 82-3204328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amro A. Albanna | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary and Director |
| Rowena Albanna | Chief Operating Officer |
| Jennifer Lee | Director of Human Resources |
| Dr. Dolly B. Tyan D(ABHI), Ph.D. | Senior Vice President of Clinical Development ? Transplantation |
| Ge Chen M.D., M.S. | Senior Vice President of Preclinical Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 8-K/A | [Amend] Current report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 8, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 8, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 1, 2025 | 8-K | Current Report |